Drugs in MeSH Category Angiogenesis Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003	AB	RX	Yes	No
Natco	THALIDOMIDE	thalidomide	CAPSULE;ORAL	213267-002	Apr 24, 2026	AB	RX	No	No
Natco	THALIDOMIDE	thalidomide	CAPSULE;ORAL	213267-004	Apr 24, 2026	AB	RX	No	No

Market dynamics and patent landscape for NLM MeSH “Angiogenesis Inhibitors” drugs

Last updated: July 18, 2026

The angiogenesis inhibitors market is shaped by a small set of high-revenue vascular endothelial growth factor (VEGF) pathway agents plus broader classes (integrin, VEGF receptor TKIs, and multikinase inhibitors). Patent estates cluster around (1) molecules and core scaffolds, (2) specific indications and method-of-use, (3) formulations (especially solubility/particle engineering for oral and biologics), and (4) combination regimens. Competitive pressure is driven by loss of composition-of-matter or primary use exclusivity, with follow-on patents and exclusivity supplements delaying generic and biosimilar entry in targeted subsets. For US commercialization, the near-term gatekeepers are Orange Book composition-of-matter and exclusivity expirations, Paragraph IV litigation posture, and the FDA interchangeability and reference product rules for biologics.

What patents protect angiogenesis inhibitors (VEGF inhibitors, integrin antagonists, and TKIs)?

Short answer: Patent protection is usually layered: composition-of-matter for the active (small molecules or biologics), formulation and dosing for manufacturability and stability, method-of-use patents for specific indications, and combination regimens. In US practice, the Orange Book captures approved-drug-specific patents; outside the Orange Book, litigated “unlisted” patents often still drive settlement leverage.

Which patent types dominate angiogenesis inhibitors?

1. Composition of matter

   • Core compound patents and scaffold families.
   • Often supplemented by stereochemistry, polymorph, and salt forms for small molecules; by biologic sequence, glycoform, and process claims for antibodies.

2. Methods of use and indication claims

   • Tumor-type specific claims (for example, metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma).
   • Line-of-therapy claims (first-line vs later-line) and biomarker-defined subpopulations.

3. Combination regimen claims

   • Co-administration with chemotherapy, immunotherapy, or radiation.
   • Fixed-dose or schedule-specific claims (same day, sequential dosing, cycle timing).

4. Formulation and device-adjacent claims

   • Oral bioavailability and particle size control for TKIs.
   • Injectable stabilization, concentration, and container-closure system claims for antibodies.

5. Manufacturing/process claims

   • Particularly relevant for biologics and for small molecules where polymorph control is critical.

How many patents cover angiogenesis inhibitor drugs on the Orange Book?

The Orange Book is not a universal proxy for global patent density, but it is the best US entry-risk map. In angiogenesis inhibitors, Orange Book listing density typically spikes around:

• launch-year composition-of-matter,
• post-approval line extensions and new indications,
• formulation updates (tablet strength, capsule, oral solution),
• and approved combination indications where specific dosing regimens are part of the label.

Because Orange Book listings are drug-product specific, patent count per asset varies strongly by:

• strength and dosage form,
• whether the same active has multiple marketed NDCs,
• and whether the applicant filed continuation patents tied to new labeling.

When do angiogenesis inhibitors lose exclusivity in the US (Orange Book and FDA exclusivity timelines)?

Short answer: The practical exclusivity end dates that govern generic entry for small molecules usually come from a mix of:

• patent expiration for listed composition and method patents, plus
• FDA exclusivity periods (new chemical entity and new molecular entity, pediatric exclusivity, and sometimes orphan drug exclusivity depending on indication),
• and any orphan exclusivity forfeiture or timing triggers.

For biologics, biosimilar timing depends on BLA reference product exclusivity and biosimilar-specific regulatory pathways rather than Orange Book.

What triggers generic entry risk for small-molecule VEGF pathway inhibitors?

Key US gate points:

• Composition-of-matter expiration for the active ingredient.
• Method-of-use patent expiration for any indication still covered by the label or by what the generic must omit.
• Exclusivity supplementers that can delay “on-label” entry even after a core patent expires.

What is the typical sequencing pattern in angiogenesis inhibitor patent estates?

Most estates follow a repeatable sequence:

• earliest expiry: older composition-of-matter,
• then follow-on expiries for specific indications and combinations,
• then the final barrier tends to be late-listed method-of-use and formulation patents tied to the most commercially meaningful label segments.

How does Paragraph IV litigation affect generic launch timing?

Paragraph IV filings can convert an exclusivity timeline into a litigation schedule:

• automatic 30-month stay of approval (if required conditions are met),
• settlements that re-route the launch date, sometimes with agreed design-arounds (label carve-outs, dosing limits),
• and court outcomes that can create either early entry or longer delay depending on injunction risk.

In angiogenesis inhibitors, disputes often focus on:

• design-around feasibility (different polymorph or formulation),
• whether the proposed generic triggers a listed method-of-use claim,
• and whether generic approval would infringe combination or biomarker-defined claims.

What is the Orange Book status of leading angiogenesis inhibitors and what patents block generics?

Short answer: For US market access, the Orange Book is the canonical listing for small molecules. Patent blocking risk concentrates in:

• listed composition-of-matter,
• listed method-of-use for oncology indications,
• and formulation patents on the specific NDC strengths being pursued.

Which angiogenesis inhibitors have the highest generic and biosimilar entry attention?

The highest attention typically concentrates on:

• blockbuster VEGF pathway inhibitors (oral TKIs) with multiple tumor indications and large label overlap, and
• high-revenue biologic VEGF/VEGFR antibodies that can attract biosimilar development.

These programs tend to have:

• dense “evergreening” filings for combinations and line extensions,
• frequent Orange Book listing updates post-approval,
• and repeated Paragraph IV waves for different strengths or indications.

How do formulation patents change the design-around strategy?

Generic entrants can sometimes avoid method patents by carving indications, but they often still face:

• formulation-specific claims (bioequivalence bridging, particle size, polymorph),
• and container/strength claims that may restrict “approved dosage form” interchangeability.

For oral angiogenesis inhibitors, formulation and solid-state patents can be a practical barrier even when method-of-use claims expire earlier.

How strong is the patent estate for anti-VEGF and VEGFR inhibitors (small molecules vs biologics)?

Short answer: Patent strength is generally strongest when:

• composition-of-matter is backed by multiple continuations,
• method-of-use includes multiple label indications with overlapping claim coverage,
• combination regimen claims are present for the highest revenue partner therapies,
• and formulation patents protect key dosage forms used in the largest market share.

What makes angiogenesis inhibitor estates “stackable”?

Stacking typically comes from:

• multi-family filings across chemical space,
• jurisdictional continuation strategies,
• and Orange Book listing updates that align patents to the highest value label.

How does the legal posture differ between small molecules and biologics?

• Small molecules: Orange Book listing and Paragraph IV litigation provide the main enforcement leverage for generics.
• Biologics: Biosimilar litigation is more constrained by biologics-specific frameworks, and enforcement focuses on reference product protection and biosimilar-related patents (including residual rights to compositions, methods, and manufacturing).

Which companies are challenging angiogenesis inhibitor patents via Paragraph IV filings or biosimilar routes?

Short answer: Challengers are usually generic manufacturers with oncology portfolios and companies that specialize in biosimilar development. Competitive behavior is shaped by:

• the number of remaining listed patents at the relevant NDC,
• likelihood of settlement vs trial risk,
• and the strategic value of the specific indication carve-outs.

What settlement structures are common in angiogenesis inhibitor cases?

Typical settlement outcomes in this class include:

• launch date agreements tied to the last-to-expire relevant patent,
• label carve-outs limited to non-infringing indications or dosing regimens,
• and design-around adjustments to avoid particular formulation or polymorph claims.

What patent litigation affects angiogenesis inhibitor approvals in the US?

Short answer: Litigation affects timing through two main levers:

1. court injunction risk or final invalidity rulings tied to Orange Book patents, and
2. settlement agreements that convert uncertain court outcomes into predictable launch schedules.

How do courts usually resolve infringement vs validity disputes in this class?

Fact patterns in angiogenesis inhibitor litigation often involve:

• claim construction on method-of-use elements tied to clinical regimens,
• whether the proposed generic label triggers infringement (particularly for combination regimens),
• and validity attacks on obviousness or lack of enablement.

Where estoppel or adverse construction occurs, it can shift all subsequent parallel cases for the same drug family.

How does biosimilar risk apply to biologic angiogenesis inhibitors?

Short answer: Biosimilar risk depends on:

• the BLA reference product exclusivity end date,
• the presence of “residual” patents that remain enforceable after exclusivity,
• and whether clinical similarity and manufacturing process patents create practical barriers.

What biosimilar pathways are most relevant?

• Full biosimilar development under FDA’s biosimilar pathway.
• Interchangeability designation where required for pharmacy substitution dynamics (less relevant for oncology early lines but important for payer contracting and utilization).

What makes biosimilar launch timing particularly sensitive in angiogenesis?

• Multiple marketed products and strengths for the same biologic.
• Combination use patterns with chemotherapy or immunotherapy that can keep method claims economically relevant.
• Manufacturing process patents that can constrain supply or force design changes.

How do combination regimens shape the patent landscape for angiogenesis inhibitors?

Short answer: Combination claims are a key economic driver. They extend protection beyond monotherapy composition-of-matter by attaching patent coverage to clinically used regimens.

What combination partners drive the most enforceable patents?

In oncology, angiogenesis inhibitors are most commonly paired with:

• chemotherapy backbones,
• immunotherapy agents,
• and radiotherapy schedules.

Patent drafting often tracks real-world clinical sequences, making label alignment and proposed generic labeling central to infringement analysis.

Which formulations of angiogenesis inhibitors are protected by patents (oral solid vs injectable biologics)?

Short answer: The most enforceable formulation patents typically protect:

• oral solid state characteristics affecting bioavailability (polymorph, particle size),
• injectable biologic stability (concentration, formulation components),
• and delivery mechanisms tied to label strengths.

What dosage forms create distinct NDC-level patent exposure?

For small molecules:

• tablet vs capsule vs solution variants can carry different Orange Book listings. For biologics:
• different strengths and concentration formats can have separate patent tethering even when the active ingredient is the same.

What generic entry risks exist for angiogenesis inhibitors by geography?

Short answer: US is the primary driver for Orange Book and Paragraph IV timing, but global risk is shaped by:

• EU Supplementary Protection Certificates (SPCs),
• national “Bolar” provisions and patent linkage frameworks,
• and enforcement intensity.

EU SPC and patent term extensions

EU SPCs for active ingredients can significantly extend effective exclusivity, especially where core compound patents expired earlier than expected. For angiogenesis inhibitors, the extension can delay generic entry even when basic patents lapse.

International litigation and enforcement patterns

Large oncology product estates often face parallel litigation:

• enabling cross-market bargaining leverage,
• and accelerating settlements when design-around is feasible in one jurisdiction but blocked in another.

What is the competitive landscape for angiogenesis inhibitors as patents expire?

Short answer: As key patents expire, competition shifts in three steps:

1. generic entry on older, lower-risk indications or dosing strengths,
2. delayed “full label” entry due to method-of-use or combination patents,
3. biosimilar entry for biologics where reference exclusivity and residual patents permit.

Revenue exposure concentration matters more than average portfolio expiry

Commercial impact depends on:

• whether the expiring patents cover the label segment generating the bulk of revenue,
• whether the company can maintain market share through indication expansions,
• and payer behavior once lower-cost options arrive.

Timeline view: how patent layers delay market erosion in angiogenesis inhibitors

Short answer: Effective exclusivity loss often occurs in phases aligned to:

• composition-of-matter expiration,
• then method-of-use expiration,
• then formulation NDC-level patents,
• then any pediatric/orphan supplements.

In practice, the last-to-expire elements determine “full commercial erosion,” while earlier expirations can cause partial erosion via carve-out or limited generic entry.

Key takeaways

• Angiogenesis inhibitor patent protection is typically layered across composition-of-matter, method-of-use, combination regimens, and formulation. The Orange Book is the highest-value map for US small-molecule entry risk.
• Market timing hinges on the last-to-expire listed patents tied to commercially meaningful label segments, not just earliest composition-of-matter expiry.
• Paragraph IV challenges and settlements are the main levers that convert patent expiry into launch schedules for generics.
• Biosimilar risk for biologic angiogenesis inhibitors is governed by BLA exclusivity and residual patents, with manufacturing and process claims often shaping practical timing.
• Combination regimen patents can extend enforceable protection far beyond monotherapy, increasing the likelihood of label carve-outs as patents expire.

FAQs

1) How do Orange Book “method of use” patents impact generic label carve-outs for angiogenesis inhibitors?
They can prevent approval for specific oncology indications or dosing regimens even when composition patents are expired, driving agreements that carve out infringing uses.

2) What role do formulation and polymorph patents play for oral VEGF pathway inhibitor generics?
They can block or delay generic approvals by restricting bioequivalence under required solid-state characteristics tied to the approved NDC strengths.

3) What patent families most often extend exclusivity for angiogenesis inhibitors after initial launch?
Continuation portfolios around indication expansions, combination regimens, and specific dosage forms.

4) How is biosimilar entry risk assessed for biologic angiogenesis inhibitors?
By sequencing BLA exclusivity end dates against residual patents tied to formulation, method, and manufacturing.

5) What settlement terms are most common in angiogenesis inhibitor Paragraph IV disputes?
Launch-date commitments with label and/or formulation design-arounds that avoid infringement of the remaining Orange Book-listed patents.

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). US Food and Drug Administration.
2. FDA. Guidance for Industry: Biosimilars. US Food and Drug Administration.
3. FDA. Drug Development and Drug Interactions (Purple Book and related regulatory materials). US Food and Drug Administration.
4. European Medicines Agency (EMA). Supplementary Protection Certificate (SPC) information resources. EMA.